News and Announcements
Arthritis Relief Plus Completes US FDA Compliance, Receives Government Support & National News Coverage
- Published August 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ARP has developed and patented a novel technology – Acteev® with its lead product – 4Jointz®, a topical botanical cream addressing a significant unmet market need. It is commercial ready for key international markets.
FY 17 Company Achievements:
- Completed US FDA compliance, securing an OTC topical drug classification for 4Jointz
Secured Australian Government support in the first cohort at the RocketSpace LandingPad in San Francisco. - Awarded new Queensland Government Ignite grant.
- Completed production of first commercial pilot batch of 4Jointz in the USA.
- Direct to consumer online sales testing for USA market commenced at www.4jointz.com
- National and regional broadcast news coverage in Australia.
investment opportunity now on offer to accelerate USA market growth and support global market partnering activities.
ABOUT ARTHRITIS RELIEF PLUS
ARP (USA) Pty Ltd has been granted the rights to commercialize 4JOINTZ® in the USA by Arthritis Relief Plus Ltd, an Australian Biotechnology company, which has developed, patented and successfully completed clinical studies of its unique botanical topical (4JOINTZ®) for pain, stiffness and swelling associated with osteoarthritis and other joint conditions.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
